Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions |
umls-concept:C0002583,
umls-concept:C0007595,
umls-concept:C0021467,
umls-concept:C0021469,
umls-concept:C0025677,
umls-concept:C0039667,
umls-concept:C0243071,
umls-concept:C0301714,
umls-concept:C0332256,
umls-concept:C0337112,
umls-concept:C0431085,
umls-concept:C0597032,
umls-concept:C1524075,
umls-concept:C1533691,
umls-concept:C2258997
|
pubmed:issue |
5
|
pubmed:dateCreated |
1986-6-20
|
pubmed:abstractText |
Analogues of the antitumor antifolate methotrexate (MTX) were synthesized in which the glutamate (Glu) moiety was replaced by ornithine (Orn), 2,4-diaminobutyric acid (Dab), or 2,3-diaminopropionic acid (Dap). An aminopterin (AMT) analogue with Orn in place of Glu was also synthesized. The MTX analogues were obtained by reaction of 4-amino-4-deoxy-N10-methylpteroic acid (mAPA) and N omega-Boc-alpha,omega-diaminoalkanoic acids in the presence of diethyl phosphorocyanidate, followed by deprotection with trifluoroacetic acid (TFA) or by reaction of p-nitrophenyl-mAPA and N omega-Boc-alpha,omega-diaminoalkanoic acids and subsequent treatment with TFA. The AMT analogue (APA-Orn) was synthesized by reaction of p-nitrophenyl 4-amino-4-deoxy-N10-formylpteroate with silylated N delta-Boc-L-ornithine in DMF at 55 degrees C for 3 days (45% yield), saponification (83%), and TFA cleavage (89%). APA-Orn was a potent inhibitor of both dihydrofolate reductase (DHFR) from L1210 mouse leukemia (IC50 = 0.072 microM) and partly purified folylpolyglutamate synthetase (FPGS) from mouse liver (Ki = 0.15 +/- 0.06 microM). The MTX analogue (mAPA-Orn) was likewise active against both enzymes, with an IC50 of 0.160 microM for DHFR and a Ki of 20.4 +/- 7.7 microM for FPGS inhibition. The other MTX analogues and the previously reported lysine derivative (mAPA-Lys) showed DHFR affinity similar to that of mAPA-Orn but lacked activity as FPGS inhibitors. The positively charged amino group appears to be detrimental to cellular uptake, as evidenced by the low cytotoxicity of these compounds (IC50 = 0.40-2.4 microM) in comparison with MTX and AMT (IC50 = 0.002 microM) against wild-type L1210 cells. On the other hand, mAPA-Orn and APA-Orn were both more potent than the corresponding Glu derivatives MTX and AMT against L1210/R81 cells, suggesting that in these MTX-resistant cells there may occur a "self-potentiation" process involving enhanced antifolate activity via interference with the polyglutamylation of reduced folates. APA-Orn is the most potent dual inhibitor of DHFR and FPGS discovered to date, but its effectiveness as a therapeutic agent may require some form of prodrug modification to neutralize the terminal amino group of the side chain.
|
pubmed:grant | |
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/2,3-diaminopropionic acid,
http://linkedlifedata.com/resource/pubmed/chemical/2,4-diaminobutyric acid,
http://linkedlifedata.com/resource/pubmed/chemical/Aminobutyric Acids,
http://linkedlifedata.com/resource/pubmed/chemical/Aminopterin,
http://linkedlifedata.com/resource/pubmed/chemical/Folic Acid Antagonists,
http://linkedlifedata.com/resource/pubmed/chemical/Glutamates,
http://linkedlifedata.com/resource/pubmed/chemical/Glutamic Acid,
http://linkedlifedata.com/resource/pubmed/chemical/Methotrexate,
http://linkedlifedata.com/resource/pubmed/chemical/Ornithine,
http://linkedlifedata.com/resource/pubmed/chemical/Peptide Synthases,
http://linkedlifedata.com/resource/pubmed/chemical/beta-Alanine,
http://linkedlifedata.com/resource/pubmed/chemical/folylpolyglutamate synthetase
|
pubmed:status |
MEDLINE
|
pubmed:month |
May
|
pubmed:issn |
0022-2623
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
29
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
655-60
|
pubmed:dateRevised |
2007-11-14
|
pubmed:meshHeading |
pubmed-meshheading:2871191-Aminobutyric Acids,
pubmed-meshheading:2871191-Aminopterin,
pubmed-meshheading:2871191-Animals,
pubmed-meshheading:2871191-Cell Division,
pubmed-meshheading:2871191-Folic Acid Antagonists,
pubmed-meshheading:2871191-Glutamates,
pubmed-meshheading:2871191-Glutamic Acid,
pubmed-meshheading:2871191-Kinetics,
pubmed-meshheading:2871191-Leukemia L1210,
pubmed-meshheading:2871191-Methotrexate,
pubmed-meshheading:2871191-Mice,
pubmed-meshheading:2871191-Molecular Weight,
pubmed-meshheading:2871191-Ornithine,
pubmed-meshheading:2871191-Peptide Synthases,
pubmed-meshheading:2871191-beta-Alanine
|
pubmed:year |
1986
|
pubmed:articleTitle |
Methotrexate analogues. 26. Inhibition of dihydrofolate reductase and folylpolyglutamate synthetase activity and in vitro tumor cell growth by methotrexate and aminopterin analogues containing a basic amino acid side chain.
|
pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, P.H.S.
|